News

According to the license and supply deal, Ligand has earned a $500,000 milestone payment. Ligand executive vice president and chief operating officer Matthew Foehr said, "Rib-X is an

The investigational therapy that is currently in Phase 2 development comprises two recombinant, gluten specific enzymes (a cysteine protease (EP-B2) and a prolyl endopeptidase (PEP)), that degrade gluten

The company has added on-site stability storage and additional GMP testing that aids in manufacturing good-quality supplies for clinical use. Bend Research vice president Tanya Hayden said the

The new rotavirus vaccine is expected to be made available at a cost of around $1 per dose, allowing poor countries to easily vaccinate their children against the

The patent application ‘Alpha Emitting Constructs and Uses Thereof’ is licensed by Actinium from Memorial Sloan Kettering Cancer Center. Actinium CMO Dragan Cicic said the decision is important

Reprints Desk’s Sunshine ePrints solution simplifies Sunshine Act compliance for the use of medical ePrints for sales, marketing and medical affairs. The solution records the delivery of each

The first fully human monoclonal antibody Sarilumab is directed against the IL-6 receptor and delivered by subcutaneous injection every other week. Regeneron Laboratories president and Regeneron chief scientific

The CMC’s CHEF1 high-productivity expression plasmid will be leveraged for the cell line development to optimize cell growth, and consistent, high-level protein expression in a rapid time frame.

BioGaia ProTectis baby drops and the BioGaia ProTectis tablets contain BioGaia’s patented and researched probiotic strain Lactobacillus reuteri Protectis. BioGaia Gastrus is a new product that is currently